Objectives-Our goal was to assess the diagnostic efficacy of ultrasound (US)-guided fine-needle aspiration (FNA) of thyroid nodules according to size and US features.
FNA, and experience available for cytologic interpretation. 5, 6 When operator experience and cytologic interpretation are excluded, size is one of the most important factors affecting the sensitivity and positive predictive value (PPV). 3, 7 For large nodules (>40 mm) and tiny nodules (5 mm), nondiagnostic and false-negative FNA results remain a problem. 3, 4, 8 Another factor affecting FNA is the US appearance of the nodule, although the exact features predicting diagnostic results are not fully characterized. Previous studies have been subject to limitations and a degree of bias. Some studies defined benign and nondiagnostic FNA results as "negative." Some studies involved cases without pathologic evidence, which might overestimate the sensitivity and specificity. 1, 3, 6 The purpose of this study was to evaluate US-guided FNA according to nodule size with a large population of histopathologically proven cases. At the same time, we investigated the correlation between false FNA results (both false positive and false negative) and the US features of the nodules.
Materials and Methods

Patients
This study was approved by the Institutional Review Board and Ethics Committee. A total of 12,230 cases of US-guided FNA were performed in our department from January 2010 to December 2014. Pathologic archives identified a total of 1767 resected thyroid nodules (by either hemithyroidectomy or full thyroidectomy) at Ruijin Hospital. Patients with incomplete clinical data were excluded. Finally, 1745 pathologically confirmed nodules that underwent preoperative FNA were enrolled in this retrospective study. In our hospital, all patients underwent US assessment of the thyroid nodules according to the Thyroid Imaging Reporting and Data System (TI-RADS) before US-guided FNA. Nodules with TI-RADS category 4A and above were considered suspicious lesions. The target nodules were determined according to the 2009 revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. 9 Patients who had tiny nodules (5mm) with suspicious US features (TI-RADS category 4A and higher) were recommended for US-guided FNA and, if necessary and desired, follow-up surgery. All follicular lesions on cytologic analysis were referred for surgery.
Clinical Data Acquisition
A total of 1745 thyroid nodules with US-guided FNA results in 1665 patients were evaluated. The electronic medical record was reviewed by 2 radiologists for the collection of clinical data for each patient, including age, sex, and the type of surgery performed. Surgery was usually performed within 3 months after US-guided FNA. The cytologic report for the thyroid FNA, including the Bethesda category and probable tumor type, and the surgical pathologic results (benign or malignant and details of the histologic type) were collected. Two radiologists correlated the US images (including the size, number, and location of the nodule tested) with the pathologic report to ensure that the nodules targeted for FNA and resection were the same.
Each nodule was recategorized according to the TI-RADS defined by Xu et al. 10 The TI-RADS includes 7 categories with malignancy risks as follows: categories 1 and 2 (0%), 3 (<2%), 4A (2%-5%), 4B (5%-50%), 4C (50%-90%) and 5 (90%). 10 After collecting and sorting data, we asked cytopathologists (the same ones who made the original diagnoses) to review slices of 60 falsenegative and 17 of false-positive cases.
Methods
Ultrasound Imaging of Thyroid Lesions
Two commercially available US scanners (MyLab 90 and MyLab 60; Esoate SpA, Genoa, Italy) with 4-13-MHz linear transducers (LA523) were used. Standard grayscale transverse and longitudinal US images of the thyroid gland, including nodules, suspicious lymph nodes, and extra abnormalities (if present, eg, extracapsular tumor extension), were obtained. Assessed nodule features included shape (taller than wide or wider than tall), borders (clear or obscure), margins (circumscribed or noncircumscribed), internal composition (solid or nonsolid), echogenicity (hypoechoic or nonhypoechoic), uniformity (heterogeneous or homogeneous), shadow (presence or absence), microcalcifications (presence or absence), vascularity (low or increased), membrane invasion, presence of diffuse diseases, and size of the thyroid.
Ultrasound-Guided FNA Informed consent was obtained from the patients before US-guided FNA was performed. Patients were examined in a supine position with an extended neck for best exposure. The location of the most suspicious nodule was determined by US visualization, and the corresponding skin area was sterilized with a 75% alcohol solution. No local anesthesia was administered before US-guided FNA. Ultrasound guidance and puncture were performed by a certified interventional radiologist (with > 1 year of experience with US-guided FNA and >100 cases) using a freehand long-axis approach to visualize the entire length of the needle and to confirm the tip position within the nodule. In general, a 22-gauge fine needle (open tip) attached to a 10-mL syringe was used for puncture. A 25-gauge fine needle was used for deeper nodules and nodules with increased vascularity. Then, aspiration was performed with the assistance of a nurse (4 nurses in our department with >than 1 year of experience with US-guided FNA and >100 cases). The needle tip was moved back and forth with suction applied and halted until tissue was aspirated into the hub of the needle. The obtained material was smeared onto 1 or 2 glass slides and air dried immediately after FNA was finished. The adequacy of smear samples was verified by these experienced nurses on gross examination. At least 2 passes were made unless the smear samples were deemed inadequate, in which case more passes were made. The slides were fixed immediately in 95% ethanol and examined after hematoxylin-eosin staining by cytopathologists.
Fine-Needle Aspiration Interpretation
Diagnosis by FNA was made by a panel of 2 experienced cytopathologists (38 and 6 years of experience) according to the Bethesda categories: I, nondiagnostic/unsatisfactory (fails to meet the criteria for cytologic adequacy that a single slide contains the presence of at least 6 groups of well-visualized follicular cells, each group containing at least 10 well-preserved epithelial cells); II, benign; III, atypia of undetermined significance/follicular lesion of undetermined significance; IV, follicular neoplasm/suspicious for follicular neoplasm, which also encompasses the diagnosis of a H€ urthle cell neoplasm/ suspicious for H€ urthle cell neoplasm; V, suspicious for malignancy; and VI, malignant.
Statistical Analyses
The 1745 cases of US-guided FNA were divided into 5 groups according to their largest diameter measured with US (5 mm as group 1, 5.1-10 mm as group 2, 10.1-15 mm as group 3, 15.1-20 mm as group 4, and >20.1 mm as group 5). True-positive and true-negative results were defined as malignant and benign for both FNA and histologic results. The diagnostic efficacy of US-guided FNA and false-negative and false-positive rates were calculated for the 5 nodule size groups among the 1369 Bethesda category II and VI US-guided FNA cases. The Pearson v 2 test was used to compare sizes between Bethesda I-VI and non-Bethesda I-VI groups. This method was also used to assess the effect of nodule size on false cytologic results (false negative and false positive) and true cytologic results (true negative and true positive). Each US feature was compared between the false-negative and true-positive groups, and the falsepositive and true-negative groups were evaluated by a single-factor analysis (Pearson v 2 ). Analyses were performed with SPSS version 16.0 software (IBM Corporation, Armonk, NY). The predetermined level of significance was set at a P < .05.
Results
Clinical Data
Among 1665 patients, 568 underwent hemithyroidectomy; 663 underwent total thyroidectomy; and 434 underwent 1-or 2-lobe subtotal thyroidectomy. Sixty patients had 2 nodules involved in this study. Twenty patients had repeated FNA, and 17 were verified to have malignancies by pathologic analysis. The interval between 2 US-guided FNA procedures was 6 months to 2 years. The mean age 6 SD for the population was 44.3 6 12.8 years (range, 14-85 years); 77.2% of the patients were female, and 22.8% were male. The mean size, as determined by the maximum dimension, was 10.8 6 7.6 mm (range, 2.0-73.0 mm). Most nodules were micronodules (nodules 10 mm in the largest US diameter), and 250 were tiny nodules (nodules 5 mm in the largest diameter); 64.6% (1000 of 1548) were microcarcinomas (carcinomas 10 mm in the largest US diameter). A total of 1548 of 1745 (88.7%) nodules in this study were malignant thyroid lesions. The malignancy rates confirmed by pathologic analysis in the 5 groups divided by size were 91.6%, 93.2%, 89.9%, 87.3%, and 59.6%, respectively. There were 1534 papillary carcinomas (including 1518 classic and 16 follicular variants), 6 follicular carcinomas, 7 medullary carcinomas, and 1 anaplastic carcinoma. A total of 197 benign nodules included 129 nodular goiters, 27 follicular adenomas, 9 H€ urthle cell adenomas, 18 Hashimoto thyroiditis cases, 3 subacute thyroiditis cases, and 11 cases of scars and fibrosis. Among follicular, medullary, and poorly differentiated carcinomas, the percentages of micronodules were 33.3%, 28.6%, and 100%.
Ultrasound, US-Guided FNA, Cytologic, and Pathologic Results The sensitivity, specificity, PPV, and accuracy of US assessment using TI-RADS were 84.0%, 62.7%, 95.0%, and 81.7%, respectively. There were 1369 benign and malignant US-guided FNA results (Bethesda II and VI cytologic results) and 376 results that were nondiagnostic, atypical lesions, follicular lesions, and suspicious for malignancy (Bethesda I, III, IV, and V). The malignancy rates of these categories were 54.0%, 41.3%, 87.5%, 69.8%, 88.0%, and 98.6% (Table 1 ). There were 74 cases of Bethesda I, 145 Bethesda II, 8 Bethesda III, 43 Bethesda IV, 251 Bethesda V, and 1224 Bethesda VI US-guided FNA results (Table 2) .
There were 1292 true US-guided FNA results (US-guided FNA cytologic results concordant with pathologic results) and 77 false US-guided FNA results (US-guided FNA cytologic results discordant with pathologic results). Eighty-five were true negative (both US-guided FNA and pathologic results were benign), and 1207 were true positive (both US-guided FNA and pathologic results were malignant). Sixty nodules were confirmed as false negative (with benign US-guided FNA and malignant histopathologic results), and 17 nodules were false positive (with malignant US-guided FNA and benign histopathologic results; Figure 1 ). Seventeen false-positive cytologic results were classified as Bethesda category VI papillary thyroid carcinomas. The pathologic results of the 17 falsepositive US-guided FNA cases included 5 nodular goiters, 4 nodular goiter nodules with necrosis and fibrosis, 4 nodular goiter nodules with atypical hyperplasia, 2 H€ urthle cell adenomas, 1 adenoma, and 1 scar showing fibrosis. The pathologic results of the 60 falsenegative US-guided FNA cases included 52 papillary thyroid carcinomas, 1 papillary thyroid carcinoma with a follicular variant, 5 papillary thyroid carcinomas with Hashimoto thyroiditis, and 2 follicular carcinomas (Table 3) . When 77 false US-guided FNA cases were reevaluated, 60 cases had the original cytologic results confirmed as benign. Of the 17 false-positive cases, 9 were confirmed as Bethesda category VI (malignant), and 8 were recategorized, including 3 cases as Bethesda V (suspicious for malignancy), 3 as Bethesda IV (suspicious for follicular neoplasm), and 2 as Bethesda III (atypia of undetermined significance/follicular lesion of undetermined significance).
Effect of Size on US-Guided FNA Results
The 74 Bethesda I US-guided FNA results were as follows: 12 (4.8%) cases in group 1, 29 (3.5%) in group 2, Micronodules refer to nodules of 10 mm or smaller (largest US diameter). There was a tendency for the false-positive rate to drop and the false-negative rate to rise as nodule size increased. The false-positive rate was highest in group 1 (5 mm) and lowest in group 5 (>20 mm; 38.5% versus 5.7%). In contrast, the false-negative rate was higher in group 5 (10.4%) than in the other groups ( Table 3) .
The US-guided FNA diagnostic value was listed according to nodule size ( Table 5 ). The total sensitivity, specificity, PPV, and accuracy with 95% confidence intervals (CIs) in this study were 95.3% (95% CI, 94.0%-96.4%), 83.6% (95% CI, 74.8%-89.9%), 98.6% (95% CI, 97.8%-99.2%), and 94.4% (95% CI, 95.6%-93.2%), respectively. The sensitivity, accuracy, PPV, and likelihood ratio (LR) for negative US-guided FNA findings were better in groups 2, 3, and 4 but worse in groups 1 and 5. The specificity, negative predictive value (NPV), LR for positive results, and Youden index increased with nodule size. Ultrasound-guided FNA showed the best sensitivity, PPV, and accuracy in group 2 (96.6%, 99.2%, and 96.0%). The specificity, NPV, LR for negative results, and Youden index were highest in group 5 (94.3%, 80.5%, 0.111, and 0.84; Table 5 ).
Otherwise, it was suggested that nodules larger than 10 mm had more Bethesda II or IV results than those smaller than 10 mm (P < .05; odds ratio [OR], 2.31 for Bethesda II and 4.74 for Bethesda IV) in this study. As the nodule size increased, this trend became more pronounced. Nodules larger than 20 mm had 4.55 and 7.09 times the likelihood of obtaining Bethesda II or IV results ( Table 6 ).
The Pearson v 2 analysis also showed that larger nodules (>20 mm) yielded more false-negative FNA results (P < .05). Larger nodules were 2.57 times more likely to have false-negative US-guided FNA results than smaller nodules, with a 95% CI of 1.17 to 5.62. Smaller nodules (5 mm) had more than 4 times the false-positive FNA rate than larger nodules (P < .05; Table 7 ).
Correlation Between, Size, US Features, and US-Guided FNA Results There were significant differences for Bethesda I cytologic results between nodules with and without some US features, including a taller-than-wide shape, clear (Table 8 ).
There were significant differences for false-negative cytologic results between nodules with and without some US features, including clear borders, circumscribed margins, a heterogeneous composition, no hypoechoic echo texture, and increased intranodular vascularity. The ORs were 4.03, 5.80, 8.43, 0.22, and 1.78 respectively. A clear border was a protective factor for false-positive FNA results, with an OR of 0.25 (Table 7) .
Discussion
Ultrasound-guided FNA is the most cost-effective method for diagnosing thyroid nodules. Prior studies have reported sensitivity of 68% to 98% and specificity of 72% to 100% for US-guided FNA. 5, 10, 11 Compared to prior studies, our total sensitivity and PPV were in the upper range, and the total specificity and NPV were in the lower range because of the small percentage of benign nodules in this pathologically based study. Previous studies reported 1.4% to 10.5% false-negative rates and 1.9% to 31% false-positive rates for US-guided FNA comparing cytologic and corresponding histopathologic results. 8, [12] [13] [14] [15] The total false-negative and false-positive rates in this study were 4.7% and 16.7%, respectively. Our false-positive rate was higher than in some reported studies. It was reported that the actual risks of malignancy in surgically excised nodules of Bethesda categories I, II, III, IV, V, and VI were 9% to 32%, 1% to 10%, 6% to 48%, 14% to 34%, 53% to 97%, and 94% to 100%, respectively. 1, 16 The malignancy rates for Bethesda categories V and VI were moderate compared to other studies. However, our malignancy rates for Bethesda categories I, II, III, and IV (54.0%, 41.3%, 87.5%, and 69.8%) were much higher than in other reported studies. These results might have been caused by a selection bias, since nodules with US-TI-RADS categories of 4A and higher were recommended for USguided FNA.
The comprehensive diagnostic efficacy of USguided FNA was best in large nodules (>20 mm). However, larger nodules tended to have more false-negative FNA results. Prior studies stated that larger (>3-cm) nodules and nodules with heterogeneous echo textures had a lower likelihood of a true-positive diagnosis. 17, 18 In this study, we achieved similar results, in that larger nodules (>20 mm) had more false-negative FNA results (Figure 2 ). On the basis of these results, we suggested that larger nodules should be subjected to an increased number of passes in different parts of the target nodules during FNA. Tiny nodules (<5 mm) tended to have a higher false-positive rate in our study. However, all nodules smaller than 5 mm showed suspicious US features (classified as 4A and above by the US TI-RADS), and 9 of 17 false-positive FNA cases were confirmed as Assuming that this conjecture is correct, some of the "false-positive cases" were actually "true positives" in this study (Figure 3 ). Another probability was that malignancies remained but were not detected on pathologic examination because the lesions were too small. Bethesda I FNA results are the main drawback of the FNA technique. Kim et al 14 reported that for 200 resected nodules smaller than 5 mm in diameter, the cytologic results tended to be nondiagnostic in tumors with small sizes. We agree with this conclusion, as tiny nodules have lower tissue volumes for aspiration ( Figure  4) . However, in this study, 14.3% (250 of 1745) of nodules were smaller than 5 mm. One poorly differentiated thyroid carcinoma was 5 mm in maximum diameter. There was no significance in the diagnostic FNA cytologic results between nodules smaller and larger than 5 mm. Although the 2016 guidelines of the American Thyroid Association do not recommend FNA in 21 suggested that increased intranodular vascularization correlated with Bethesda I US-guided FNA results, but other US features, such as intranodular calcifications and the consistency of nodules, did not. In this study, we found that nodules with benign US characteristics, such as clear borders, regular margins, nonsolid components, nonhypoechoic properties, the absence of microcalcifications, and the absence of a taller-than-wide shape, were more likely to be categorized as Bethesda category I. We suggest that all nodules should undergo standardized FNA procedures, even if they appear benign on US examinations to avoid insufficient FNA results. Increased intranodular vascularity was a risk factor for false-negative results in our study. When suspicious nodules with a high blood supply are targeted for FNA, multiple passes, particularly into the most suspicious parts of the nodules, and possibly different techniques (fine-needle capillary aspiration and FNA) to avoid bloody aspiration may be needed. A clear border was a protective factor that was correlated with false-positive FNA cases in this study. In other words, nodules with an obscure border were more likely to have false-positive FNA results. However, this finding did not have a specific reason, since an obscure border was a common US feature in suspicious and malignant thyroid nodules. It is possible that the cytopathologist might have given an "aggressive" diagnosis in some cases. Since cytologic specimens only provide a few cells and tissues in part of the lesion, the diagnostic cytologic criteria for thyroid malignancy differ from those used in histopathologic analyses. Cytologic diagnosis is more challenging and requires an experienced cytopathologist. The limitations of cytology should be acknowledged.
The main limitation of this retrospective study was the selection bias, since all of the nodules were pathologically proven, and the numbers of benign nodules were few. Another was that we did not control for the factors of FNA techniques and operator experience. Further studies are needed to investigate the factors influencing FNA results.
In conclusion, US-guided FNA should be the first choice for the initial diagnosis of thyroid nodules because of its convenience and effectiveness as a diagnostic test. Nodules larger than 20 mm may require more passes to avoid false FNA results. Larger nodules with some benign US features and increased vascularity may increase the probabilities of Bethesda category I and false-negative results. Tiny nodules and an obscure border were risk factors for false-positive US-guided FNA results.
